ALT5 Sigma
Minneapolis
About ALT5 Sigma
JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $1.5B
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:ALTS
- Website: alt5sigma.com
- Phone: +1 952-930-9000
Industries & Categories
Biotechnology, Health Care, Recycling
Social Profiles
Canonical: https://fsome.com/organization/alt5-sigma-94963 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.